RxDoctor Payments Data

Roger Samawi, DO

Family Medicine · Long Beach, CANPI 1275570822

Payments from drug & device makers

$1,564in general payments, 2019–2025

Across 70 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$401
  • Novo Nordisk$283
  • Lilly USA, LLC$174
  • Boehringer Ingelheim$73
  • Gilead$70
  • Eisai Inc.$60
  • plus $502 from 12 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$1,564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,564 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$46,367
Medicare patients
135
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$90,848
FarxigaDapagliflozin Propanediol77$89,993
OzempicSemaglutide68$82,474
JardianceEmpagliflozin71$76,086
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$63,805
EliquisApixaban58$56,817
TrulicityDulaglutide43$53,096
JanuviaSitagliptin Phosphate38$41,739
MounjaroTirzepatide22$23,096
MyrbetriqMirabegron26$22,239
XareltoRivaroxaban18$11,107
Breo ElliptaFluticasone/Vilanterol15$10,169
GemtesaVibegron11$7,136
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$7,043
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$6,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$401$89,99377 claims
Novo NordiskOzempic$283$82,47468 claims
Lilly USA, LLCTrulicity, Mounjaro$174$76,19265 claims
Boehringer IngelheimJardiance$73$76,08671 claims
GSKTrelegy Ellipta, Breo Ellipta$54$73,97469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →